Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. SRPT Peers
See (SRPT) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SRPT | $20.94 | -42.12% | 2.1B | -7.93 | -$2.64 | N/A |
| VRTX | $450.91 | -1.00% | 115.8B | -117.73 | -$3.83 | N/A |
| REGN | $522.68 | -1.24% | 55.5B | 13.29 | $39.32 | +0.34% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $308.90 | +0.30% | 40.3B | -147.80 | -$2.09 | N/A |
| ARGX | $551.11 | -4.63% | 33.7B | 33.58 | $16.41 | N/A |
| BNTX | $106.33 | -0.23% | 25.6B | -28.97 | -$3.67 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| RPRX | $35.10 | +0.75% | 19.7B | 14.27 | $2.46 | +2.45% |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
SRPT vs VRTX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, VRTX has a market cap of 115.8B. Regarding current trading prices, SRPT is priced at $20.94, while VRTX trades at $450.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas VRTX's P/E ratio is -117.73. In terms of profitability, SRPT's ROE is -0.20%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, SRPT is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs REGN Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, REGN has a market cap of 55.5B. Regarding current trading prices, SRPT is priced at $20.94, while REGN trades at $522.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas REGN's P/E ratio is 13.29. In terms of profitability, SRPT's ROE is -0.20%, compared to REGN's ROE of +0.15%. Regarding short-term risk, SRPT is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs SGEN Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SRPT is priced at $20.94, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SRPT's ROE is -0.20%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, SRPT is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs ALNY Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, ALNY has a market cap of 40.3B. Regarding current trading prices, SRPT is priced at $20.94, while ALNY trades at $308.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas ALNY's P/E ratio is -147.80. In terms of profitability, SRPT's ROE is -0.20%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, SRPT is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs ARGX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, ARGX has a market cap of 33.7B. Regarding current trading prices, SRPT is priced at $20.94, while ARGX trades at $551.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas ARGX's P/E ratio is 33.58. In terms of profitability, SRPT's ROE is -0.20%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, SRPT is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs BNTX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, BNTX has a market cap of 25.6B. Regarding current trading prices, SRPT is priced at $20.94, while BNTX trades at $106.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas BNTX's P/E ratio is -28.97. In terms of profitability, SRPT's ROE is -0.20%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, SRPT is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs BGNE Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SRPT is priced at $20.94, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SRPT's ROE is -0.20%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, SRPT is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs RPRX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, RPRX has a market cap of 19.7B. Regarding current trading prices, SRPT is priced at $20.94, while RPRX trades at $35.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas RPRX's P/E ratio is 14.27. In terms of profitability, SRPT's ROE is -0.20%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, SRPT is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs DNA-WT Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SRPT is priced at $20.94, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SRPT's ROE is -0.20%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, SRPT is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs SMMT Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, SMMT has a market cap of 14.7B. Regarding current trading prices, SRPT is priced at $20.94, while SMMT trades at $19.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas SMMT's P/E ratio is -58.68. In terms of profitability, SRPT's ROE is -0.20%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, SRPT is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs GMAB Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, GMAB has a market cap of 14.2B. Regarding current trading prices, SRPT is priced at $20.94, while GMAB trades at $22.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas GMAB's P/E ratio is 13.45. In terms of profitability, SRPT's ROE is -0.20%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, SRPT is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs INCY Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, INCY has a market cap of 13.8B. Regarding current trading prices, SRPT is priced at $20.94, while INCY trades at $71.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas INCY's P/E ratio is 356.10. In terms of profitability, SRPT's ROE is -0.20%, compared to INCY's ROE of +0.01%. Regarding short-term risk, SRPT is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs UTHR Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, UTHR has a market cap of 13B. Regarding current trading prices, SRPT is priced at $20.94, while UTHR trades at $288.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas UTHR's P/E ratio is 11.50. In terms of profitability, SRPT's ROE is -0.20%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, SRPT is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs KRTX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SRPT is priced at $20.94, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SRPT's ROE is -0.20%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, SRPT is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs EXEL Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, EXEL has a market cap of 11.4B. Regarding current trading prices, SRPT is priced at $20.94, while EXEL trades at $41.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas EXEL's P/E ratio is 19.06. In terms of profitability, SRPT's ROE is -0.20%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, SRPT is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs BMRN Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, SRPT is priced at $20.94, while BMRN trades at $56.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas BMRN's P/E ratio is 20.83. In terms of profitability, SRPT's ROE is -0.20%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, SRPT is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs ASND Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, ASND has a market cap of 10.7B. Regarding current trading prices, SRPT is priced at $20.94, while ASND trades at $177.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas ASND's P/E ratio is -26.60. In terms of profitability, SRPT's ROE is -0.20%, compared to ASND's ROE of +1.91%. Regarding short-term risk, SRPT is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs MRNA Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, MRNA has a market cap of 10.1B. Regarding current trading prices, SRPT is priced at $20.94, while MRNA trades at $26.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas MRNA's P/E ratio is -2.98. In terms of profitability, SRPT's ROE is -0.20%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, SRPT is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs RXDX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SRPT is priced at $20.94, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SRPT's ROE is -0.20%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SRPT is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs IMGN Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SRPT is priced at $20.94, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SRPT's ROE is -0.20%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, SRPT is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs BPMC Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, BPMC has a market cap of 8.3B. Regarding current trading prices, SRPT is priced at $20.94, while BPMC trades at $128.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas BPMC's P/E ratio is -51.10. In terms of profitability, SRPT's ROE is -0.20%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, SRPT is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs CERE Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SRPT is priced at $20.94, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas CERE's P/E ratio is -16.47. In terms of profitability, SRPT's ROE is -0.20%, compared to CERE's ROE of -0.43%. Regarding short-term risk, SRPT is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs TECH Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, TECH has a market cap of 8.1B. Regarding current trading prices, SRPT is priced at $20.94, while TECH trades at $51.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas TECH's P/E ratio is 62.20. In terms of profitability, SRPT's ROE is -0.20%, compared to TECH's ROE of +0.06%. Regarding short-term risk, SRPT is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs VRNA Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, VRNA has a market cap of 7.9B. Regarding current trading prices, SRPT is priced at $20.94, while VRNA trades at $92.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas VRNA's P/E ratio is -46.35. In terms of profitability, SRPT's ROE is -0.20%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, SRPT is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs ROIVW Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, SRPT is priced at $20.94, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, SRPT's ROE is -0.20%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, SRPT is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs BBIO Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, BBIO has a market cap of 7.8B. Regarding current trading prices, SRPT is priced at $20.94, while BBIO trades at $41.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas BBIO's P/E ratio is -11.56. In terms of profitability, SRPT's ROE is -0.20%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, SRPT is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs ROIV Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, ROIV has a market cap of 7.5B. Regarding current trading prices, SRPT is priced at $20.94, while ROIV trades at $11.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas ROIV's P/E ratio is -14.77. In terms of profitability, SRPT's ROE is -0.20%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, SRPT is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs CORT Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, CORT has a market cap of 7.5B. Regarding current trading prices, SRPT is priced at $20.94, while CORT trades at $70.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas CORT's P/E ratio is 61.65. In terms of profitability, SRPT's ROE is -0.20%, compared to CORT's ROE of +0.20%. Regarding short-term risk, SRPT is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs RVMD Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, RVMD has a market cap of 7.4B. Regarding current trading prices, SRPT is priced at $20.94, while RVMD trades at $39.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas RVMD's P/E ratio is -9.58. In terms of profitability, SRPT's ROE is -0.20%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, SRPT is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs HALO Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, HALO has a market cap of 6.6B. Regarding current trading prices, SRPT is priced at $20.94, while HALO trades at $53.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas HALO's P/E ratio is 14.34. In terms of profitability, SRPT's ROE is -0.20%, compared to HALO's ROE of +1.22%. Regarding short-term risk, SRPT is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs JAZZ Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, JAZZ has a market cap of 6.6B. Regarding current trading prices, SRPT is priced at $20.94, while JAZZ trades at $109.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas JAZZ's P/E ratio is 14.90. In terms of profitability, SRPT's ROE is -0.20%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, SRPT is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs RETA Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SRPT is priced at $20.94, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas RETA's P/E ratio is -66.29. In terms of profitability, SRPT's ROE is -0.20%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SRPT is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs MDGL Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, MDGL has a market cap of 6.3B. Regarding current trading prices, SRPT is priced at $20.94, while MDGL trades at $285.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas MDGL's P/E ratio is -15.97. In terms of profitability, SRPT's ROE is -0.20%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, SRPT is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs AMRN Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, AMRN has a market cap of 5.7B. Regarding current trading prices, SRPT is priced at $20.94, while AMRN trades at $13.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas AMRN's P/E ratio is -3.16. In terms of profitability, SRPT's ROE is -0.20%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, SRPT is more volatile compared to AMRN. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs TLX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, TLX has a market cap of 5.7B. Regarding current trading prices, SRPT is priced at $20.94, while TLX trades at $16.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas TLX's P/E ratio is 186.11. In terms of profitability, SRPT's ROE is -0.20%, compared to TLX's ROE of +0.14%. Regarding short-term risk, SRPT is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs TGTX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, TGTX has a market cap of 5.7B. Regarding current trading prices, SRPT is priced at $20.94, while TGTX trades at $35.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas TGTX's P/E ratio is 142.52. In terms of profitability, SRPT's ROE is -0.20%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, SRPT is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs IONS Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, IONS has a market cap of 5.6B. Regarding current trading prices, SRPT is priced at $20.94, while IONS trades at $35.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas IONS's P/E ratio is -11.79. In terms of profitability, SRPT's ROE is -0.20%, compared to IONS's ROE of -0.92%. Regarding short-term risk, SRPT is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs ABCM Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SRPT is priced at $20.94, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SRPT's ROE is -0.20%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SRPT is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs ISEE Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SRPT is priced at $20.94, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SRPT's ROE is -0.20%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SRPT is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs NUVL Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, NUVL has a market cap of 5.5B. Regarding current trading prices, SRPT is priced at $20.94, while NUVL trades at $76.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas NUVL's P/E ratio is -16.52. In terms of profitability, SRPT's ROE is -0.20%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, SRPT is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs AXSM Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, AXSM has a market cap of 5B. Regarding current trading prices, SRPT is priced at $20.94, while AXSM trades at $101.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas AXSM's P/E ratio is -17.62. In terms of profitability, SRPT's ROE is -0.20%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, SRPT is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs ADMA Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, ADMA has a market cap of 4.9B. Regarding current trading prices, SRPT is priced at $20.94, while ADMA trades at $20.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas ADMA's P/E ratio is 24.29. In terms of profitability, SRPT's ROE is -0.20%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, SRPT is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs ALKS Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, SRPT is priced at $20.94, while ALKS trades at $29.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas ALKS's P/E ratio is 14.00. In terms of profitability, SRPT's ROE is -0.20%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, SRPT is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs ALPN Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SRPT is priced at $20.94, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SRPT's ROE is -0.20%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, SRPT is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs ZLAB Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, ZLAB has a market cap of 4.5B. Regarding current trading prices, SRPT is priced at $20.94, while ZLAB trades at $40.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas ZLAB's P/E ratio is -16.25. In terms of profitability, SRPT's ROE is -0.20%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, SRPT is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs AKRO Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, AKRO has a market cap of 4.4B. Regarding current trading prices, SRPT is priced at $20.94, while AKRO trades at $55.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas AKRO's P/E ratio is -14.88. In terms of profitability, SRPT's ROE is -0.20%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, SRPT is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs PCVX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, PCVX has a market cap of 4.4B. Regarding current trading prices, SRPT is priced at $20.94, while PCVX trades at $34.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas PCVX's P/E ratio is -8.60. In terms of profitability, SRPT's ROE is -0.20%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, SRPT is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs OPT Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SRPT is priced at $20.94, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas OPT's P/E ratio is -1.52. In terms of profitability, SRPT's ROE is -0.20%, compared to OPT's ROE of +2.60%. Regarding short-term risk, SRPT is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs MRTX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SRPT is priced at $20.94, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SRPT's ROE is -0.20%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, SRPT is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs PTCT Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, PTCT has a market cap of 4.1B. Regarding current trading prices, SRPT is priced at $20.94, while PTCT trades at $51.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas PTCT's P/E ratio is 7.97. In terms of profitability, SRPT's ROE is -0.20%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, SRPT is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs CYTK Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, CYTK has a market cap of 4B. Regarding current trading prices, SRPT is priced at $20.94, while CYTK trades at $33.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas CYTK's P/E ratio is -6.38. In terms of profitability, SRPT's ROE is -0.20%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, SRPT is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs RYTM Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, RYTM has a market cap of 4B. Regarding current trading prices, SRPT is priced at $20.94, while RYTM trades at $62.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas RYTM's P/E ratio is -22.28. In terms of profitability, SRPT's ROE is -0.20%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, SRPT is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs MRUS Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, MRUS has a market cap of 4B. Regarding current trading prices, SRPT is priced at $20.94, while MRUS trades at $53.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas MRUS's P/E ratio is -12.81. In terms of profitability, SRPT's ROE is -0.20%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, SRPT is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs SLNO Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, SLNO has a market cap of 3.9B. Regarding current trading prices, SRPT is priced at $20.94, while SLNO trades at $78.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas SLNO's P/E ratio is -16.49. In terms of profitability, SRPT's ROE is -0.20%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, SRPT is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs KRYS Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, KRYS has a market cap of 3.8B. Regarding current trading prices, SRPT is priced at $20.94, while KRYS trades at $133.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas KRYS's P/E ratio is 31.90. In terms of profitability, SRPT's ROE is -0.20%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, SRPT is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs RYZB Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, SRPT is priced at $20.94, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SRPT's ROE is -0.20%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SRPT is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs CBAY Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, SRPT is priced at $20.94, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SRPT's ROE is -0.20%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, SRPT is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs ACAD Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, SRPT is priced at $20.94, while ACAD trades at $22.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas ACAD's P/E ratio is 16.16. In terms of profitability, SRPT's ROE is -0.20%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, SRPT is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs RNA Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, RNA has a market cap of 3.6B. Regarding current trading prices, SRPT is priced at $20.94, while RNA trades at $29.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas RNA's P/E ratio is -9.93. In terms of profitability, SRPT's ROE is -0.20%, compared to RNA's ROE of -0.27%. Regarding short-term risk, SRPT is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs CRSP Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, CRSP has a market cap of 3.6B. Regarding current trading prices, SRPT is priced at $20.94, while CRSP trades at $41.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas CRSP's P/E ratio is -9.26. In terms of profitability, SRPT's ROE is -0.20%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, SRPT is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs SWTX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, SRPT is priced at $20.94, while SWTX trades at $46.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas SWTX's P/E ratio is -13.74. In terms of profitability, SRPT's ROE is -0.20%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, SRPT is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs ACLX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, ACLX has a market cap of 3.5B. Regarding current trading prices, SRPT is priced at $20.94, while ACLX trades at $64.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas ACLX's P/E ratio is -21.43. In terms of profitability, SRPT's ROE is -0.20%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, SRPT is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs RARE Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, RARE has a market cap of 3.5B. Regarding current trading prices, SRPT is priced at $20.94, while RARE trades at $37.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas RARE's P/E ratio is -6.37. In terms of profitability, SRPT's ROE is -0.20%, compared to RARE's ROE of -1.86%. Regarding short-term risk, SRPT is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs PTGX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, PTGX has a market cap of 3.4B. Regarding current trading prices, SRPT is priced at $20.94, while PTGX trades at $54.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas PTGX's P/E ratio is 70.08. In terms of profitability, SRPT's ROE is -0.20%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, SRPT is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs LEGN Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, LEGN has a market cap of 3.3B. Regarding current trading prices, SRPT is priced at $20.94, while LEGN trades at $35.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas LEGN's P/E ratio is -30.37. In terms of profitability, SRPT's ROE is -0.20%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, SRPT is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs SRRK Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, SRRK has a market cap of 3.1B. Regarding current trading prices, SRPT is priced at $20.94, while SRRK trades at $32.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas SRRK's P/E ratio is -12.60. In terms of profitability, SRPT's ROE is -0.20%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, SRPT is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs KYMR Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, KYMR has a market cap of 3.1B. Regarding current trading prices, SRPT is priced at $20.94, while KYMR trades at $46.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas KYMR's P/E ratio is -15.06. In terms of profitability, SRPT's ROE is -0.20%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, SRPT is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs VKTX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, VKTX has a market cap of 3B. Regarding current trading prices, SRPT is priced at $20.94, while VKTX trades at $26.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas VKTX's P/E ratio is -23.24. In terms of profitability, SRPT's ROE is -0.20%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, SRPT is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs CRNX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, CRNX has a market cap of 2.9B. Regarding current trading prices, SRPT is priced at $20.94, while CRNX trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas CRNX's P/E ratio is -8.22. In terms of profitability, SRPT's ROE is -0.20%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, SRPT is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs CPRX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, CPRX has a market cap of 2.9B. Regarding current trading prices, SRPT is priced at $20.94, while CPRX trades at $23.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas CPRX's P/E ratio is 15.08. In terms of profitability, SRPT's ROE is -0.20%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, SRPT is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs MORF Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, SRPT is priced at $20.94, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas MORF's P/E ratio is -14.88. In terms of profitability, SRPT's ROE is -0.20%, compared to MORF's ROE of -0.22%. Regarding short-term risk, SRPT is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs MOR Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, SRPT is priced at $20.94, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas MOR's P/E ratio is -12.64. In terms of profitability, SRPT's ROE is -0.20%, compared to MOR's ROE of +2.51%. Regarding short-term risk, SRPT is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs MTSR Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, MTSR has a market cap of 2.8B. Regarding current trading prices, SRPT is priced at $20.94, while MTSR trades at $26.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas MTSR's P/E ratio is -10.62. In terms of profitability, SRPT's ROE is -0.20%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, SRPT is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs AAPG Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, AAPG has a market cap of 2.8B. Regarding current trading prices, SRPT is priced at $20.94, while AAPG trades at $32.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas AAPG's P/E ratio is -43.42. In terms of profitability, SRPT's ROE is -0.20%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, SRPT is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs IBRX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, IBRX has a market cap of 2.8B. Regarding current trading prices, SRPT is priced at $20.94, while IBRX trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas IBRX's P/E ratio is -5.49. In terms of profitability, SRPT's ROE is -0.20%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, SRPT is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs MLTX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, MLTX has a market cap of 2.7B. Regarding current trading prices, SRPT is priced at $20.94, while MLTX trades at $42.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas MLTX's P/E ratio is -18.65. In terms of profitability, SRPT's ROE is -0.20%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, SRPT is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs KDNY Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, SRPT is priced at $20.94, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas KDNY's P/E ratio is -12.47. In terms of profitability, SRPT's ROE is -0.20%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, SRPT is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs IMVT Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, IMVT has a market cap of 2.6B. Regarding current trading prices, SRPT is priced at $20.94, while IMVT trades at $15.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas IMVT's P/E ratio is -5.67. In terms of profitability, SRPT's ROE is -0.20%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, SRPT is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs MYOV Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, SRPT is priced at $20.94, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas MYOV's P/E ratio is -14.05. In terms of profitability, SRPT's ROE is -0.20%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, SRPT is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs APGE Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, APGE has a market cap of 2.5B. Regarding current trading prices, SRPT is priced at $20.94, while APGE trades at $42.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas APGE's P/E ratio is -11.82. In terms of profitability, SRPT's ROE is -0.20%, compared to APGE's ROE of -0.19%. Regarding short-term risk, SRPT is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs MIRM Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, MIRM has a market cap of 2.5B. Regarding current trading prices, SRPT is priced at $20.94, while MIRM trades at $50.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas MIRM's P/E ratio is -31.32. In terms of profitability, SRPT's ROE is -0.20%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, SRPT is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs XENE Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, XENE has a market cap of 2.5B. Regarding current trading prices, SRPT is priced at $20.94, while XENE trades at $32.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas XENE's P/E ratio is -9.94. In terms of profitability, SRPT's ROE is -0.20%, compared to XENE's ROE of -0.32%. Regarding short-term risk, SRPT is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs PRVB Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, SRPT is priced at $20.94, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas PRVB's P/E ratio is -16.43. In terms of profitability, SRPT's ROE is -0.20%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, SRPT is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs LBPH Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, SRPT is priced at $20.94, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas LBPH's P/E ratio is -26.66. In terms of profitability, SRPT's ROE is -0.20%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, SRPT is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs NAMSW Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, NAMSW has a market cap of 2.3B. Regarding current trading prices, SRPT is priced at $20.94, while NAMSW trades at $9.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas NAMSW's P/E ratio is N/A. In terms of profitability, SRPT's ROE is -0.20%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, SRPT is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for SRPT.
SRPT vs APLS Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, APLS has a market cap of 2.3B. Regarding current trading prices, SRPT is priced at $20.94, while APLS trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas APLS's P/E ratio is -10.17. In terms of profitability, SRPT's ROE is -0.20%, compared to APLS's ROE of -1.00%. Regarding short-term risk, SRPT is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs DICE Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, SRPT is priced at $20.94, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas DICE's P/E ratio is -21.91. In terms of profitability, SRPT's ROE is -0.20%, compared to DICE's ROE of +0.56%. Regarding short-term risk, SRPT is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs LGND Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, LGND has a market cap of 2.2B. Regarding current trading prices, SRPT is priced at $20.94, while LGND trades at $115.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas LGND's P/E ratio is -15.78. In terms of profitability, SRPT's ROE is -0.20%, compared to LGND's ROE of -0.16%. Regarding short-term risk, SRPT is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs NAMS Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, NAMS has a market cap of 2.2B. Regarding current trading prices, SRPT is priced at $20.94, while NAMS trades at $19.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas NAMS's P/E ratio is -10.73. In terms of profitability, SRPT's ROE is -0.20%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, SRPT is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs ARWR Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, SRPT is priced at $20.94, while ARWR trades at $15.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas ARWR's P/E ratio is -12.66. In terms of profitability, SRPT's ROE is -0.20%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, SRPT is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs BCRX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, BCRX has a market cap of 2.2B. Regarding current trading prices, SRPT is priced at $20.94, while BCRX trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas BCRX's P/E ratio is -39.57. In terms of profitability, SRPT's ROE is -0.20%, compared to BCRX's ROE of +0.11%. Regarding short-term risk, SRPT is more volatile compared to BCRX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs CALT Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, SRPT is priced at $20.94, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas CALT's P/E ratio is -22.73. In terms of profitability, SRPT's ROE is -0.20%, compared to CALT's ROE of -1.67%. Regarding short-term risk, SRPT is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs DNLI Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, DNLI has a market cap of 2.1B. Regarding current trading prices, SRPT is priced at $20.94, while DNLI trades at $14.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas DNLI's P/E ratio is -5.58. In terms of profitability, SRPT's ROE is -0.20%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, SRPT is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs VCEL Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, SRPT is priced at $20.94, while VCEL trades at $41.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas VCEL's P/E ratio is 831.80. In terms of profitability, SRPT's ROE is -0.20%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, SRPT is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs VCYT Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, SRPT is priced at $20.94, while VCYT trades at $26.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas VCYT's P/E ratio is 63.43. In terms of profitability, SRPT's ROE is -0.20%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, SRPT is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs KNSA Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, KNSA has a market cap of 2.1B. Regarding current trading prices, SRPT is priced at $20.94, while KNSA trades at $28.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas KNSA's P/E ratio is -118.37. In terms of profitability, SRPT's ROE is -0.20%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, SRPT is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs AGIO Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, AGIO has a market cap of 2.1B. Regarding current trading prices, SRPT is priced at $20.94, while AGIO trades at $35.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas AGIO's P/E ratio is 3.10. In terms of profitability, SRPT's ROE is -0.20%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, SRPT is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs RXRX Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, RXRX has a market cap of 2B. Regarding current trading prices, SRPT is priced at $20.94, while RXRX trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas RXRX's P/E ratio is -2.78. In terms of profitability, SRPT's ROE is -0.20%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, SRPT is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.
SRPT vs IDYA Comparison
SRPT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRPT stands at 2.1B. In comparison, IDYA has a market cap of 2B. Regarding current trading prices, SRPT is priced at $20.94, while IDYA trades at $22.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRPT currently has a P/E ratio of -7.93, whereas IDYA's P/E ratio is -6.13. In terms of profitability, SRPT's ROE is -0.20%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, SRPT is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for SRPT.